LAGOS, Nigeria – A new drug combination has been found to cut the risk of death by over 40 per cent in men whose prostate cancer returns after surgery or radiation, according to findings published in The New England Journal of Medicine.
The breakthrough therapy combines enzalutamide with standard hormone treatment and shows remarkable success in patients with recurrent prostate cancer that resists conventional options.
“After initial treatment, some patients see their cancer return aggressively. Hormone therapy alone hasn’t improved survival for decades. These findings are a real game changer,” said Dr Stephen Freedland, co-principal investigator and director at Cedars-Sinai Cancer.
The trial, involving more than 1,000 patients across 17 countries, revealed that men who received the combination therapy had a 40.3 per cent lower risk of death compared to those on hormone therapy alone.
“This identifies a treatment that significantly prolongs survival in men with aggressive prostate cancer,” said Dr Hyung Kim, Chair of Urology at Cedars-Sinai.
The results, presented at the European Society for Medical Oncology Congress in Berlin, are expected to change clinical guidelines globally and provide new hope to thousands of men living with the disease.
Join the conversation